Nicotinamide microcapsules, a method for preparing the same and use thereof

Abstract

This invention relates to the field of biotechnology, and more particularly to a nicotinamide microcapsule, its preparation method, and its uses. The preparation method of the nicotinamide microcapsule includes the following steps: mixing gelatin and water and then heating the mixture to obtain a gelatin solution; under constant temperature conditions of 38-45℃, sequentially dissolving L-α-glycine phosphate, sodium alginate, isomaltooligosaccharide, nicotinamide, and vitamin C in the gelatin solution to obtain a mixed solution; adjusting the pH of the mixed solution and then continuously stirring to obtain the nicotinamide microcapsule. This nicotinamide microcapsule exhibits good encapsulation effect and high encapsulation rate, demonstrating excellent encapsulation ability for nicotinamide, effectively improving the absorption efficiency of nicotinamide, and enabling nicotinamide to be converted into more NAD+. + This leads to the production of more ATP, thereby increasing the bioavailability of nicotinamide.

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a nicotinamide microcapsule, its preparation method, and its uses. Background Technology

[0002] With the surge in demand for anti-aging products, cellular-level anti-aging has become a trend. Niacinamide (NAM), a B vitamin, possesses properties that enhance skin barrier function, inhibit melanin production, and reduce inflammation, demonstrating significant potential in the anti-aging field. Research indicates that niacinamide (NAM) is a precursor to NAD+. + Nicotinic acid adenine dinucleotide (NAD) is an important precursor that can be converted into NAD. + NAD + Increased levels can effectively promote ATP production, thereby enhancing cellular energy metabolism. However, as a bioactive substance, NAM has poor stability and is easily affected by enzymatic hydrolysis and the acidic environment of the stomach during metabolism in vivo, leading to its decomposition or degradation and loss of activity, resulting in poor bioavailability.

[0003] Currently, existing technologies primarily employ microencapsulation to protect the activity of nicotinamide. This microencapsulation technique involves encapsulating nicotinamide in microcapsules using physical processes such as spray drying and coagulation baths. However, this method has significant limitations: encapsulated materials prepared under high temperature or high pressure environments are unstable, potentially leading to premature release of nicotinamide and reduced bioavailability.

[0004] Therefore, developing a method to improve the stability of nicotinamide has become an urgent technical problem to be solved. Summary of the Invention

[0005] This invention provides a method for preparing nicotinamide microcapsules. This method can produce nicotinamide microcapsules with good encapsulation effect and high encapsulation rate, exhibiting excellent encapsulation ability for nicotinamide. It effectively protects the activity of nicotinamide, improves its absorption efficiency, and enables nicotinamide to be converted into more NAD+. + This leads to the production of more ATP, thereby increasing the bioavailability of nicotinamide.

[0006] This invention also provides a nicotinamide microcapsule prepared by the above-described method. Therefore, this nicotinamide microcapsule has good encapsulation effect and high encapsulation rate, exhibiting excellent encapsulation ability for nicotinamide. It can effectively protect the activity of nicotinamide, improve the absorption efficiency of nicotinamide, and enable nicotinamide to be converted into more NAD+. + This leads to the production of more ATP, thereby increasing the bioavailability of nicotinamide.

[0007] This invention also provides the use of the above-described nicotinamide microcapsules, or nicotinamide microcapsules prepared by the above-described method, in the preparation of a formulation that promotes cellular energy metabolism, which is used to increase ATP levels. The inventors' research shows that using the nicotinamide microcapsules of this invention can generate more ATP.

[0008] The first aspect of the present invention provides a method for preparing nicotinamide microcapsules, comprising the following steps:

[0009] Gelatin is mixed with water and then heated to obtain a gelatin solution.

[0010] Under constant temperature conditions of 38-45℃, L-α-glycine choline, sodium alginate, isomaltooligosaccharide, nicotinamide and vitamin C were dissolved in the gelatin solution in sequence to obtain a mixed solution;

[0011] The nicotinamide microcapsules were obtained by continuously stirring the solution after adjusting its pH value.

[0012] The preparation method of nicotinamide microcapsules as described above, by mass parts, comprises 3-6 parts of gelatin, 2-5 parts of L-α-glycine choline, 2-5 parts of sodium alginate, 18-25 parts of isomaltooligosaccharide, 5-15 parts of nicotinamide, and 0.5-3 parts of vitamin C.

[0013] In the preparation method of nicotinamide microcapsules as described above, the mass ratio of gelatin to water in the gelatin solution is 1:(15-20).

[0014] The nicotinamide microcapsules prepared as described above have a spindle-shaped structure.

[0015] In the preparation method of nicotinamide microcapsules as described above, the particle size of the gelatin is ≤300 mesh, the particle size of the L-α-glycine choline is ≤300 mesh, the particle size of the sodium alginate is ≤300 mesh, the particle size of the isomaltooligosaccharide is ≤300 mesh, the particle size of the nicotinamide is ≤300 mesh, and the particle size of the vitamin C is ≤300 mesh.

[0016] The method for preparing nicotinamide microcapsules as described above, wherein adjusting the pH value of the mixed solution includes:

[0017] The pH of the mixed solution was adjusted to 3.8-4.2 using a pH adjuster.

[0018] The pH adjuster is citric acid.

[0019] In the preparation method of nicotinamide microcapsules as described above, the heating treatment temperature is 35-40℃ and the time is 3-5 min.

[0020] In the preparation method of nicotinamide microcapsules as described above, the continuous stirring speed is 200-500 r / min and the time is 20-30 min.

[0021] A second aspect of the present invention provides a nicotinamide microcapsule prepared by the method described above.

[0022] A third aspect of the present invention provides the use of the nicotinamide microcapsules described above or nicotinamide microcapsules prepared by the method described above in the preparation of an agent that promotes cellular energy metabolism, wherein the agent that promotes cellular energy metabolism is used to increase ATP content.

[0023] The solution of the present invention has at least the following effects:

[0024] The method for preparing nicotinamide microcapsules provided by this invention, through the synergistic effect between nicotinamide and substances such as gelatin and L-α-glucosinolate, can prepare nicotinamide microcapsules with good encapsulation effect and high encapsulation rate. These microcapsules have excellent encapsulation ability for nicotinamide, effectively protecting its activity, improving its absorption efficiency, and enabling nicotinamide to be converted into more nicotinic acid adenine dinucleotide (NAD). + This method generates more ATP, thereby improving the bioavailability of nicotinamide. It eliminates the need for traditional physical encapsulation processes such as spray drying and coagulation baths, avoiding the premature release of nicotinamide caused by high temperature or high pressure environments in traditional methods. It has the advantages of simple process and low cost. This method shortens and simplifies the capsule preparation process, providing a rapid and efficient method for the preparation of microcapsules, which is suitable for widespread application. Attached Figure Description

[0025] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0026] Figure 1 This is a scanning electron microscope image of the nicotinamide microcapsules in Example 1 of the present invention;

[0027] Figure 2 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 1 of the present invention;

[0028] Figure 3 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 2 of the present invention;

[0029] Figure 4This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 3 of the present invention;

[0030] Figure 5 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 4 of the present invention;

[0031] Figure 6 This is a particle size diagram of the nicotinamide microcapsules in Example 1 of the present invention. Detailed Implementation

[0032] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions in the embodiments of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are only some embodiments of this invention, not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0033] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available; and the processes used are conventional processes in the art.

[0034] It should be noted that the descriptions involving "first," "second," "third," "fourth," etc. in this invention are used to distinguish similar objects and are not used to describe a specific order or sequence, and therefore should not be construed as limiting the invention.

[0035] The first aspect of the present invention provides a method for preparing nicotinamide microcapsules, comprising the following steps:

[0036] Gelatin is mixed with water and then heated to obtain a gelatin solution.

[0037] Under constant temperature conditions of 38-45℃, L-α-glycine choline, sodium alginate, isomaltooligosaccharide, nicotinamide and vitamin C were dissolved in gelatin solution in sequence to obtain a mixed solution;

[0038] After adjusting the pH of the mixed solution, continuous stirring was performed to obtain nicotinamide microcapsules.

[0039] The present invention does not impose any particular limitation on the specific source of the above-mentioned raw materials, which can be purchased from commercial channels.

[0040] The aforementioned niacinamide (NAM) is a B vitamin and a precursor to NAD+ (nicotinic acid adenine dinucleotide). It enhances skin barrier function, inhibits melanin production, and reduces inflammation. Niacinamide can be converted into NAD+. + NAD + Increased levels can effectively promote ATP production, thereby enhancing cellular energy metabolism.

[0041] In this invention, the nicotinamide microcapsules are in liquid form.

[0042] First, gelatin is heated to prepare a gelatin solution. Heating transforms the gelatin into a liquid state, forming a homogeneous solution that facilitates subsequent mixing with other ingredients, providing a foundation for the formation of nicotinamide microcapsules. Under constant temperature conditions of 38-45℃, L-α-glycine choline is dissolved in the gelatin solution to obtain a first mixture. Then, sodium alginate is dissolved in the first mixture to obtain a second mixture. Next, isomaltooligosaccharide is dissolved in the second mixture to obtain a third mixture. Then, nicotinamide is dissolved in the third mixture to obtain a fourth mixture. Finally, vitamin C is dissolved in the fourth mixture to obtain a final mixture. Solution; Adjust the pH of the mixed solution and continuously stir to obtain nicotinamide microcapsules. The purpose of continuously stirring after adjusting the pH of the mixed solution is to maximize the expansion of the molecular network structure of the wall material (gelatin, sodium alginate, isomaltooligosaccharide and vitamin C) under the action of charge. Then, under the action of continuous stirring (providing shear mechanical force), the core material (nicotinamide and L-α-glucosinolate) is synergistically embedded in the expanded molecular network structure of the wall material, so that the expanded molecular network structure can fully capture the core material (nicotinamide and L-α-glucosinolate), thereby forming nicotinamide microcapsules.

[0043] The present invention, through the above-described preparation method, can prepare nicotinamide microcapsules with good encapsulation effect and high encapsulation rate. These microcapsules exhibit excellent encapsulation ability for nicotinamide, effectively protecting its activity, improving its absorption efficiency, and enabling nicotinamide to be converted into more NAD+. + This method generates more ATP, thereby improving the bioavailability of nicotinamide. It eliminates the need for traditional physical encapsulation processes such as spray drying and coagulation baths, avoiding the premature release of nicotinamide caused by high temperature or high pressure environments in traditional methods. It has the advantages of simple process and low cost. This method shortens and simplifies the capsule preparation process, providing a rapid and efficient method for the preparation of microcapsules, which is suitable for widespread application.

[0044] In one specific embodiment, by weight parts, there are 3-6 parts gelatin, 2-5 parts L-α-glycine choline, 2-5 parts sodium alginate, 18-25 parts isomaltooligosaccharide, 5-15 parts nicotinamide, and 0.5-3 parts vitamin C.

[0045] When the mass parameters of gelatin, L-α-glucosinolate, sodium alginate, isomaltooligosaccharide, nicotinamide, and vitamin C are all within the above-mentioned ranges, the components can effectively exert a synergistic effect, thereby preparing nicotinamide microcapsules with good encapsulation effect and high encapsulation rate.

[0046] Furthermore, by weight, the ingredients are: 5 parts gelatin, 3 parts L-α-glycine choline, 3 parts sodium alginate, 20 parts isomaltooligosaccharide, 10 parts nicotinamide, and 1.5 parts vitamin C.

[0047] When the mass parameters of gelatin, L-α-glucosinolate, sodium alginate, isomaltooligosaccharide, nicotinamide, and vitamin C are all within the above-mentioned values, the components can exert a more effective synergistic effect, thereby preparing nicotinamide microcapsules with better encapsulation effect and higher encapsulation rate.

[0048] In one specific embodiment, the mass ratio of gelatin to water in the above-mentioned gelatin solution is 1:(15-20), for example, the mass ratio of gelatin to water is 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, etc.

[0049] When the mass ratio of gelatin to water in the gelatin solution is within the above range, it is beneficial for the gelatin solution to mix evenly with components such as L-α-glycine choline, sodium alginate, isomaltooligosaccharide, nicotinamide, and vitamin C. Furthermore, localized gelation is less likely to occur at the specified pH value, which is conducive to the subsequent preparation of nicotinamide microcapsules with good encapsulation effect and high encapsulation rate.

[0050] In one specific embodiment, the nicotinamide microcapsules have a spindle-shaped structure.

[0051] In this invention, the nicotinamide microcapsules have a spindle-shaped structure, which has a large specific surface area and can more effectively protect nicotinamide.

[0052] In one specific embodiment, the particle size of the gelatin is ≤300 mesh, the particle size of the L-α-glycine choline is ≤300 mesh, the particle size of the sodium alginate is ≤300 mesh, the particle size of the isomaltooligosaccharide is ≤300 mesh, the particle size of the nicotinamide is ≤300 mesh, and the particle size of the vitamin C is ≤300 mesh.

[0053] In this invention, particle size ≤300 mesh refers to a positive number of particle size ≤300 mesh.

[0054] When the particle size of gelatin, L-α-glycine choline, sodium alginate, isomaltooligosaccharide, nicotinamide, and vitamin C is ≤300 mesh, the particle size of each component can be controlled to be uniform, which facilitates uniform mixing and full contact between the components and prevents clumping or aggregation. Among them, gelatin, sodium alginate, isomaltooligosaccharide, and vitamin C are used as wall materials, and nicotinamide and L-α-glycine choline are used as core materials.

[0055] In one specific embodiment, adjusting the pH value of the mixed solution includes: adjusting the pH value of the mixed solution to 3.8-4.2 using a pH adjuster.

[0056] This invention uses a pH adjuster to adjust the pH of the mixed solution to 3.8-4.2, which allows the molecular network structure of the wall material (gelatin, sodium alginate, isomaltooligosaccharide, and vitamin C) to expand to the maximum extent under the action of charge. This is beneficial for capturing (encapsulating) more core material (nicotinamide and L-α-glucosinolate), thereby preparing nicotinamide microcapsules with good encapsulation effect and high encapsulation rate.

[0057] In one specific embodiment, the pH adjuster is citric acid.

[0058] When the pH adjuster is citric acid, the molecular network structure of the wall material (gelatin, sodium alginate, isomaltooligosaccharide, and vitamin C) can be maximized under the influence of charge. This is beneficial for increasing the contact area with the core material (nicotinamide and L-α-glucosinolate), capturing (encapsulating) more of the core material (nicotinamide and L-α-glucosinolate), thereby preparing nicotinamide microcapsules with good encapsulation effect and high encapsulation rate.

[0059] In one specific embodiment, the temperature of the above-mentioned heat treatment is 35-40°C and the time is 3-5 minutes.

[0060] When the temperature and time parameters of the heat treatment are within the above range, the gelatin can be completely dissolved, avoiding local overheating or insufficient dissolution.

[0061] For example, the temperature of the heat treatment can be any one or a combination of any two of 35°C, 36°C, 37°C, 38°C, 39°C, and 40°C.

[0062] The time can be any one of 3 minutes, 4 minutes, 5 minutes, or a range of any two of them.

[0063] In one specific embodiment, the stirring speed is 200-500 r / min and the stirring time is 20-30 min.

[0064] For example, the continuous stirring speed is any one or any combination of two of the following: 200 r / min, 250 r / min, 300 r / min, 350 r / min, 400 r / min, 450 r / min, and 500 r / min.

[0065] The time can be any one or any combination of 20 min, 21 min, 22 min, 23 min, 24 min, 25 min, 26 min, 27 min, 28 min, 29 min, and 30 min.

[0066] When the stirring speed and time are within the aforementioned ranges, nicotinamide and L-α-glucosinolate in the mixed solution can be embedded into the extended molecular network structure of the wall material under the action of shear mechanical force, promoting the formation of nicotinamide microcapsules. If the stirring time is too short (less than 20 min), the wall material will fail to effectively encapsulate the core material; if the stirring time is too long (more than 30 min), the microcapsule structure will be destroyed.

[0067] A second aspect of this invention provides a nicotinamide microcapsule prepared by the method described above. Therefore, this nicotinamide microcapsule exhibits good encapsulation effect and high encapsulation rate, demonstrating excellent encapsulation ability for nicotinamide. It effectively protects the activity of nicotinamide, improves its absorption efficiency, and enables nicotinamide to be converted into more NAD+. + This leads to the production of more ATP, thereby increasing the bioavailability of nicotinamide.

[0068] A third aspect of the present invention provides the use of the above-described nicotinamide microcapsules or nicotinamide microcapsules prepared by the above-described method in the preparation of an agent that promotes cellular energy metabolism, the agent being used to increase ATP content.

[0069] The present invention will be further described below through specific embodiments.

[0070] Example 1

[0071] This embodiment provides a method for preparing nicotinamide microcapsules, including the following steps:

[0072] (1) Gelatin, L-α-glycine choline, sodium alginate, isomaltooligosaccharide, nicotinamide, and vitamin C were sieved through a 300-mesh sieve to obtain gelatin with a particle size ≤300 mesh, L-α-glycine choline with a particle size ≤300 mesh, sodium alginate with a particle size ≤300 mesh, isomaltooligosaccharide with a particle size ≤300 mesh, nicotinamide with a particle size ≤300 mesh, and vitamin C with a particle size ≤300 mesh, respectively.

[0073] (2) By mass, 5 parts of gelatin with a particle size ≤300 mesh and 90 parts of water are mixed and heated at 40°C for 5 minutes to prepare a gelatin solution;

[0074] (3) Under constant temperature of 40℃, 3 parts of L-α-glucosinolate with a particle size ≤300 mesh, 3 parts of sodium alginate with a particle size ≤300 mesh, 20 parts of isomaltooligosaccharide with a particle size ≤300 mesh, 10 parts of nicotinamide with a particle size ≤300 mesh and 1.5 parts of vitamin C with a particle size ≤300 mesh were dissolved in gelatin solution to obtain a mixed solution;

[0075] (4) After adjusting the pH of the mixed solution to 4 with citric acid, the solution was continuously stirred at 300 r / min for 20 min to obtain nicotinamide microcapsules.

[0076] Example 2

[0077] The preparation method of nicotinamide microcapsules provided in this embodiment is basically the same as that in Example 1, except that:

[0078] (4) After adjusting the pH of the mixed solution to 3.8 with citric acid.

[0079] Example 3

[0080] The preparation method of nicotinamide microcapsules provided in this embodiment is basically the same as that in Example 1, except that:

[0081] (4) After adjusting the pH of the mixed solution to 4.2 with citric acid.

[0082] Comparative Example 1

[0083] The preparation method of nicotinamide microcapsules provided in this comparative example is basically the same as that in Example 1, except that:

[0084] Replace the gelatin with soy protein isolate.

[0085] Comparative Example 2 (without gelatin)

[0086] The preparation method of nicotinamide microcapsules provided in this comparative example is basically the same as that in Example 1, except that:

[0087] (1) L-α-glycine phosphate, sodium alginate, isomaltooligosaccharide, nicotinamide and vitamin C were sieved through a 300-mesh sieve to obtain L-α-glycine phosphate with a particle size ≤300 mesh, sodium alginate with a particle size ≤300 mesh, isomaltooligosaccharide with a particle size ≤300 mesh, nicotinamide with a particle size ≤300 mesh and vitamin C with a particle size ≤300 mesh, respectively.

[0088] (2) By mass fraction, 3 parts of sodium alginate with a particle size ≤300 mesh and 90 parts of water are mixed and heated at 40°C for 5 minutes to prepare sodium alginate solution.

[0089] (3) Under constant temperature of 40℃, 3 parts of L-α-glucosinolate with a particle size ≤300 mesh, 20 parts of isomaltooligosaccharide with a particle size ≤300 mesh, 10 parts of nicotinamide with a particle size ≤300 mesh and 1.5 parts of vitamin C with a particle size ≤300 mesh were dissolved in sodium alginate solution to obtain a mixed solution;

[0090] (4) After adjusting the pH of the mixed solution to 4 with citric acid, the solution was continuously stirred at 300 r / min for 20 min to obtain nicotinamide microcapsules.

[0091] Comparative Example 3 (without sodium alginate)

[0092] The preparation method of nicotinamide microcapsules provided in this comparative example is basically the same as that in Example 1, except that:

[0093] (3) Under constant temperature of 40℃, 3 parts of L-α-glucosinolate with a particle size ≤300 mesh, 20 parts of isomaltooligosaccharide with a particle size ≤300 mesh, 10 parts of nicotinamide with a particle size ≤300 mesh and 1.5 parts of vitamin C with a particle size ≤300 mesh are dissolved in gelatin solution to obtain a mixed solution.

[0094] Comparative Example 4 (without L-α-glucosinolate)

[0095] The preparation method of nicotinamide microcapsules provided in this comparative example is basically the same as that in Example 1, except that:

[0096] (3) Under constant temperature of 40℃, 3 parts of sodium alginate with a particle size ≤300 mesh, 20 parts of isomaltooligosaccharide with a particle size ≤300 mesh, 10 parts of nicotinamide with a particle size ≤300 mesh and 1.5 parts of vitamin C with a particle size ≤300 mesh are dissolved in gelatin solution to obtain a mixed solution.

[0097] Results Explanation

[0098] 1. Scanning electron microscopy test

[0099] Scanning electron microscopy was performed on the nicotinamide microcapsules in Example 1 and Comparative Examples 1-4 of this invention. Figure 1 This is a scanning electron microscope image of the nicotinamide microcapsules in Example 1 of the present invention. Figure 2 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 1 of the present invention. Figure 3 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 2 of the present invention. Figure 4 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 3 of the present invention. Figure 5 This is a scanning electron microscope image of the nicotinamide microcapsules in Comparative Example 4 of the present invention.

[0100] Depend on Figure 1 As can be seen, the nicotinamide microcapsules in Example 1 of the present invention have a distinct microcapsule structure, which is a spindle-shaped structure. The spindle-shaped structure has a large specific surface area, which can more effectively protect nicotinamide.

[0101] Depend on Figure 2 It can be seen that no obvious microcapsule structure was observed in the nicotinamide microcapsules in Comparative Example 1 of the present invention.

[0102] Depend on Figure 3 It can be seen that no obvious microcapsule structure was observed in the nicotinamide microcapsules in Comparative Example 2 of the present invention.

[0103] Depend on Figure 4 It can be seen that the nicotinamide microcapsules in Comparative Example 3 of the present invention have obvious microcapsule structures, which are irregular flat structures and structurally unstable.

[0104] Depend on Figure 5 As can be seen, the nicotinamide microcapsules in Comparative Example 4 of the present invention have a distinct microcapsule structure, which is an irregular circular structure.

[0105] 2. Particle size test

[0106] After confirming the presence of a microcapsule structure in the nicotinamide microcapsules of Example 1 of the present invention, particle size testing was performed on the nicotinamide microcapsules in Example 1. Figure 6 This is a particle size diagram of the nicotinamide microcapsules in Example 1 of the present invention.

[0107] Depend on Figure 6 It can be seen that the nicotinamide microcapsules in Example 1 of the present invention have a particle size of about 1000 nm and have good uniformity.

[0108] 3. Embedding rate test

[0109] The encapsulation efficiency of nicotinamide microcapsules in Examples 1-3 and Comparative Examples 1-4 of this invention was tested using high performance liquid chromatography (HPLC). The test results are shown in Table 1.

[0110] Table 1 Test Results

[0111]

[0112]

[0113] As shown in Table 1, comparing Example 1 with Comparative Examples 1-4, it was found that the nicotinamide microcapsules in Example 1 of the present invention had the best encapsulation effect, high encapsulation rate, and good encapsulation ability for nicotinamide.

[0114] 4. Measurement of intracellular ATP content

[0115] The ATP content of the nicotinamide microcapsules in Example 1 and Comparative Examples 1-4 of this invention was determined using in vitro simulated human gastrointestinal digestion technology. The specific methods are as follows:

[0116] Undigested sample: Weigh 100 mg of sample, dissolve it in 50 mL of 0.9% NaCl, add 0.5 mL of 1 mol / L HCl to obtain an undigested solution.

[0117] The digested sample: The in vitro simulated digestion process lasted 4 hours and was divided into two stages: ① First stage, gastric digestion: 100 mg of sample was weighed, dissolved in 50 mL of 0.9% NaCl, 0.5 mL of 1 mol / L HCl was added, followed by 150 mg of pepsin to obtain a mixture. The mixture was placed in a constant temperature shaking incubator at 37°C in the dark for 2 hours to obtain the gastric digested solution; ② Second stage, intestinal digestion: 10 mL of 0.5 mol / L NaHCO3 solution was added dropwise to the gastric digested solution, followed by 18 mL of a mixture (containing 2 mg / mL trypsin solution and 12 mg / mL bile salt, V:V = 12:6). The mixture was incubated at 37°C in the dark for 2 hours to obtain the intestinal digested solution.

[0118] The nicotinamide microcapsules of Example 1 and Comparative Examples 1-4 of the present invention were used as samples, and undigested solutions, gastric digested solutions and intestinal digested solutions of Example 1 and each comparative example were obtained according to the above method.

[0119] Samples were taken from the undigested solution, the gastric digested solution, and the intestinal digested solution of Example 1 and each comparative example. Then, 1 mL of extraction buffer (extraction buffer from the ATP content assay kit (Shanghai Fuda Testing Technology Group Co., Ltd.)) was added to each sample, and the samples were homogenized on ice. After centrifugation at 12000 rpm and 4℃ for 10 min, the supernatant was collected, and the ATP content was determined according to the instructions of the ATP content assay kit (Shanghai Fuda Testing Technology Group Co., Ltd.). The ATP content determination results are shown in Table 2.

[0120] Table 2 Results of ATP content determination

[0121] project ATP content (μmol / mL) Undigested solution (Example 1) 0.730 Solution after gastric digestion (Example 1) 0.927 Solution after intestinal digestion (Example 1) 0.610 Undigested solution (Comparative Example 1) 0.683 The solution after gastric digestion (Comparative Example 1) 0.772 Solution after intestinal digestion (Comparative Example 1) 0.516 Undigested solution (Comparative Example 2) 0.604 Solution after gastric digestion (Comparative Example 2) 0.781 Solution after intestinal digestion (Comparative Example 2) 0.508 Undigested solution (Comparative Example 3) 0.682 Solution after gastric digestion (Comparative Example 3) 0.789 Solution after intestinal digestion (Comparative Example 3) 0.598 Undigested solution (Comparative Example 4) 0.634 The solution after gastric digestion (Comparative Example 4) 0.788 Solution after intestinal digestion (Comparative Example 4) 0.523

[0122] During gastrointestinal digestion and absorption, the absorption of many nutrients occurs through active transport, which requires ATP for energy. High ATP levels indicate a stronger active transport capacity in cells, enabling them to transport nutrients from the intestines against their concentration gradient into the cells, thereby improving nutrient absorption efficiency. Table 2 shows that, comparing Example 1 with Comparative Examples 1-4, the ATP content of the nicotinamide microcapsules in Example 1 (undigested), the nicotinamide microcapsules in Example 1 (digested in the stomach), and the nicotinamide microcapsules in Example 1 (digested in both the stomach and intestines) was higher than that in Comparative Examples 1-4. This demonstrates that the nicotinamide microcapsules prepared using the method of this invention can effectively improve the absorption efficiency of nicotinamide, enabling it to be converted into more NAD+. + This leads to the production of more ATP, thereby increasing the bioavailability of nicotinamide.

[0123] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for preparing nicotinamide microcapsules, characterized in that, Includes the following steps: Gelatin is mixed with water and then heated to obtain a gelatin solution. Under constant temperature conditions of 38-45℃, L-α-glycine choline, sodium alginate, isomaltooligosaccharide, nicotinamide and vitamin C were dissolved in the gelatin solution in sequence to obtain a mixed solution; The pH of the mixed solution was adjusted to 3.8-4.2 with citric acid and then continuously stirred to obtain the nicotinamide microcapsules; the nicotinamide microcapsules have a spindle-shaped structure.

2. The method for preparing nicotinamide microcapsules according to claim 1, characterized in that, By weight, the gelatin is 3-6 parts, the L-α-glycine choline is 2-5 parts, the sodium alginate is 2-5 parts, the isomaltooligosaccharide is 18-25 parts, the nicotinamide is 5-15 parts, and the vitamin C is 0.5-3 parts.

3. The method for preparing nicotinamide microcapsules according to claim 1, characterized in that, In the gelatin solution, the mass ratio of gelatin to water is 1:(15-20).

4. The method for preparing nicotinamide microcapsules according to claim 1, characterized in that, The particle size of the gelatin is ≤300 mesh, the particle size of the L-α-glycine choline is ≤300 mesh, the particle size of the sodium alginate is ≤300 mesh, the particle size of the isomaltooligosaccharide is ≤300 mesh, the particle size of the nicotinamide is ≤300 mesh, and the particle size of the vitamin C is ≤300 mesh.

5. The method for preparing nicotinamide microcapsules according to claim 1, characterized in that, The heat treatment is performed at a temperature of 35-40℃ for 3-5 minutes.

6. The method for preparing nicotinamide microcapsules according to claim 1, characterized in that, The continuous stirring speed is 200-500 r / min and the time is 20-30 min.

7. A nicotinamide microcapsule, characterized in that, It is prepared by the method for preparing nicotinamide microcapsules according to any one of claims 1-6.

Images